COMPANY:

Hedera

"Hedera Dx...announces the publication of an analytical validation for a pan-cancer NGS liquid biopsy solution based on a unique decentralized and international multicenter study."

"Hedera Dx...announce that the Institute of Pathology at the Technical University of Munich (TUM) has successfully passed the QuIP proficiency test for the detection of ESR1 mutations in breast cancer patients using the Hedera Profiling 2 ctDNA Test Panel (HP2)."

"Hedera Dx...has unveiled a fully streamlined solution that allows hospitals to adopt liquid biopsy testing locally for their patients with minimal efforts. The solution is a combination of laboratory reagents and a software platform...The solution is called Hedera Profiling 2 ctDNA Test Panel and it integrates easily with the existing instrument infrastructure of a hospital lab. The test is built on actionability, in other words focusing on finding a potential treatment."

"Swiss cancer liquid biopsy startup Hedera Dx is hoping to fill an unmet need in the cancer sequencing market, offering hospitals and community oncology providers a blood-based sequencing test and interpretation tool that can be rapidly deployed and easily kept in compliance with evolving regulatory requirements."

"Swiss techbio company Hedera Dx...will be launching this fall a blood-based testing solution to profile cancer DNA circulating in the blood, helping patients access better treatments. To do this, the company has raised €14M in funding."